-
[show abstract]
[hide abstract]
ABSTRACT: MicroRNAs (miRNAs) are short non-protein-coding RNAs that post-transcriptionally regulate mRNA expression. A large body of evidence has identified important roles for these regulators in cell proliferation, differentiation, apoptosis and metabolism, as well as activation of oncogenic and antioncogenic signals. Aberrant expression of miRNAs has been found in most human malignancies and is strongly associated with tumorigenesis, prediction, diagnosis, progress, treatment and prognosis. Thus, miRNAs may become an intriguing and promising therapeutic target for many diseases, including cancer. In addition, research into miRNAs may provide insight into the mechanisms underlying tumor occurrence, progression and metastasis. This review summarizes the current knowledge of miRNAs, their roles in lung cancer and avenues for future research.
Experimental Biology and Medicine 02/2012; 237(3):227-35. · 2.64 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To compare the efficacy of gefitinib monotherapy across different age groups of patients with advanced lung adenocarcinoma.
Clinical data of patients (mostly Chinese) with advanced lung adenocarcinoma who were non-smokers or light smokers and had received oral gefitinib (250mg/d) between October 2006 and December 2009 were reviewed retrospectively. The 93 enrolled patients (25 male and 68 female; median age, 62.5 years), were divided into three age groups: < or = 49 years (n = 22), 50-69 years (n = 53), and > or = 70 years (n = 18). Among them, 84 patients had received at least one chemotherapy regimen previously. The objective response rate (ORR), time to disease progression (TTP), median overall survival (MOS) and adverse effects in response to gefitinib treatment were analyzed in the above age groups.
Out of 93 patients, a complete response was seen in 5 patients, partial response in 43 patients, stable disease in 36 patients, and disease progression in 9 patients. ORR was 51.6%, and the disease control rate (DCR) was 90.3%. No significant correlation was observed between ORR of gefitinib treatment and the baseline clinical characteristics of the patients. The median TTP was 12.6 months, and median overall survival (MOS) was 23.4 months. Gefitinib treatment-related UP was prolonged with increasing age: 8.2 months, 14.2 months and 18.2 months in the age groups of < or = 49-years, 50-69-years and > or = 70-years, respectively (log-rank P = 0.002). MOS in the three age groups was 20.4 months, 23.6 months and 22.0 months, respectively (P > 0.05). The most common adverse effects were rash and diarrhoea, and rash seemed to be correlated with ORR (ORR = 2.631; p = 0.044, 95% CI: 1.025-6.753).
In Asian patients with advanced lung adenocarcinoma who were non-smokers or light smokers and were treated with gefitinib, progression-free survival was correlated with age. Elderly patients (> or = 70 years) seemed more likely to benefit from gefitinib treatment.
Pharmazie 01/2012; 67(1):80-5. · 1.01 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: It was only 3 years ago that the fusion gene between echinoderm microtubule-associated protein-like4 (EML4) and anaplastic lymphoma kinase (ALK) has been identified in a subset of non-small cell lung cancer (NSCLC). EML4-ALK is most often detected in never smokers with lung adenocarcinoma and has unique pathologic features. EML4-ALK fusion gene is oncogenic, which could be suppressed by ALK-inhibitor through blocking the downstream signaling passway of EML4-ALK. This review will focus on the molecular structure, function, biology, detection method and the diagnostic and therapeutic meaning of EML4-ALK of lung cancer.
Zhongguo fei ai za zhi = Chinese journal of lung cancer 06/2011; 14(6):538-42.
-
[show abstract]
[hide abstract]
ABSTRACT: Postoperative recurrence is the main cause of primary treatment failure in the resectable non-small cell lung cancer (NSCLC). Systematic treatments should be taken to decrease the recurrence. Adjuvant chemotherapy, including neoadjuvant chemotherapy, postoperative adjuvant chemotherapy and targeted therapy, is a widely used in this area. In this review, we summarize the clinical trials and meta-analysis related to the adjuvant chemotherapy and targeted therapy in patients with early stage NSCLC.
Zhongguo fei ai za zhi = Chinese journal of lung cancer 03/2011; 14(3):281-5.
-
[show abstract]
[hide abstract]
ABSTRACT: Treatment of unresectable nonsmall cell lung cancer (NSCLC) remains challenging. The epidermal growth factor receptor tyrosine kinase inhibitors are promising for patients with aberrant epidermal growth factor receptor activation in tumors. However, little is known whether erlotinib alone could benefit patients with advanced NSCLC. Here, the authors reported a case in which erlotinib alone stabilized stage IIIA (N2) NSCLC, leading to curative resection of lung tumors and invaded mediastinal lymph nodes. After lobectomy, the patient was followed up for 11 months without tumor recurrence. They also briefly reviewed recent literatures and discussed the implication of our findings in the treatment of advanced NSCLC.
The American Journal of the Medical Sciences 10/2010; 340(4):321-5. · 1.39 Impact Factor
-
Zhongguo fei ai za zhi = Chinese journal of lung cancer 07/2010; 13(7):748-52.
